Aclarion Announces First Commercial Agreement with Scripps Health
03 Março 2025 - 8:00AM
Aclarion, Inc.,
(“Aclarion” or the “Company”)
(Nasdaq: ACON, ACONW)
, a healthcare
technology company that is leveraging biomarkers and proprietary
augmented intelligence (AI) algorithms to help physicians identify
the location of chronic low back pain, announced today it has
established a commercial agreement with Scripps Health in San
Diego, CA. The agreement brings Nociscan to southern California and
the leading spine physicians of Scripps Green and Scripps Health,
the largest healthcare system in the San Diego area.
“Each year at Scripps, we evaluate a large, growing number of
patients suffering from chronic low back pain,” said Robert
Eastlack, MD, Orthopedic Surgeon, Scripps Health. “I have a
keen interest in advanced diagnostics and clinical decision support
tools like Nociscan. Over the last few years, I have referred
numerous patients to Beverly Hills for Nociscan. The additional
information unique from Nociscan has been valuable to me and my
patients. Having Nociscan available at Scripps Green will greatly
expand access to my colleagues and our patients in important
ways.”
Scripps Health is a nonprofit health care system that includes
five hospitals and 19 outpatient facilities and treats a
half-million patients annually through 2,600 affiliated physicians.
The system also includes clinical research and medical education
programs.
“Dr. Eastlack is a leader within Scripps, as well as the San
Diego Spine Foundation and the International Spine Study Group,
having published over 100 peer-reviewed articles and contributing
to nearly a dozen textbooks,” said Ryan Bond, Chief Strategy
Officer of Aclarion. “We are pleased to bring Nociscan to Scripps
Health and the millions of people throughout Southern California.
Dr. Eastlack and his colleagues will now be able to utilize
Nociscan in clinic and within on-going research trials, both of
which are vitally important to their mission of advancing spine
care.”
Chronic low back pain (cLBP) is a global healthcare problem with
approximately 266 million people worldwide suffering from
degenerative spine disease and low back pain. Aclarion’s Nociscan
solution is the first evidence-supported SaaS platform to
noninvasively help physicians distinguish between painful and
nonpainful discs in the lumbar spine. Nociscan objectively
quantifies chemical biomarkers demonstrated to be associated with
disc pain. When used with other diagnostic tools, Nociscan provides
critical insights into the location of a patient’s low back
pain.
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email:
info@aclarion.com
This press release is for informational purposes only and is not
intended to and shall not constitute an offer to sell or the
solicitation of an offer to sell or to buy any securities or a
solicitation of any proxy, consent, vote or approval with respect
to any securities of Aclarion, Inc. No offer, sale, issuance or
transfer of securities shall be made in any jurisdiction in which
such offer, sale, issuance or transfer would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages
Magnetic Resonance Spectroscopy (“MRS”), proprietary signal
processing techniques, biomarkers, and augmented intelligence
algorithms to optimize clinical treatments. The Company is first
addressing the chronic low back pain market with Nociscan, the
first, evidence-supported, SaaS platform to noninvasively help
physicians distinguish between painful and nonpainful discs in the
lumbar spine. Through a cloud connection, Nociscan receives
magnetic resonance spectroscopy (MRS) data from an MRI machine for
each lumbar disc being evaluated. In the cloud, proprietary signal
processing techniques extract and quantify chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to indicate if a disc may be a
source of pain. When used with other diagnostic tools, Nociscan
provides critical insights into the location of a patient’s low
back pain, giving physicians clarity to optimize treatment
strategies. For more information, please
visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 about the Company’s current
expectations about future results, performance, prospects and
opportunities. Statements that are not historical facts, such as
“anticipates,” “believes” and “expects” or similar expressions, are
forward-looking statements. These forward-looking statements are
based on the current plans and expectations of management and are
subject to a number of uncertainties and risks that could
significantly affect the Company’s current plans and expectations,
as well as future results of operations and financial condition.
These and other risks and uncertainties are discussed more fully in
our filings with the Securities and Exchange Commission. Readers
are encouraged to review the section titled “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023, as well as other disclosures contained in the Prospectus
and subsequent filings made with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contacts:
Kirin M. SmithPCG Advisory, Inc.ksmith@pcgadvisory.com
Media Contacts:
Jennie KimSPRIG Consultingjennie@sprigconsulting.com
Aclarion (NASDAQ:ACONW)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Aclarion (NASDAQ:ACONW)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025